nb02
Non Hodgkin Lymphoma (NHL)
NOBO MedicinePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the Non Hodgkin Lymphoma (NHL) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Blinatumomab St. Jude Children's Research Hospital | Phase 2 | B |
Anti-Thymoglobulin, Rabbit St. Jude Children's Research Hospital | Phase 2 | CCC |
cd45ra-depleted dli St. Jude Children's Research Hospital | Phase 2 | CCC |
il-15 Medical College of Wisconsin | Phase 1/2 | CC |
kt-333 Kymera Therapeutics, Inc. | Phase 1 | CC |
Ala-101 Arovella Therapeutics Ltd | Phase 1 | CC |
Vancomycin Abramson Cancer Center at Penn Medicine | Phase 1 | CC |
POSELTINIB NOBO Medicine | Phase 1 | CC |
Same molecule, other indications
nb02 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →